Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome

Inclusion Criteria: * Type 2 Diabetes Mellitus * Fasting triglycerides ≥ 1,7 mmol/l * Acute coronary syndrome at least before 5 and maximum 21 days before the inclusion * If previously treated with statin therapy, the dose should be equivalent to 40 mg of simvastatin at inclusion * In case of previous statin therapy, last LDL-C measurement before event should be ≤ 2,6 mmol/l * Written informed consent obtained Exclusion Criteria: * Heart failure IV class (NYHA) * Acute decompensated heart failure * Life expectancy no more than 1 year * Chronic kidney disease (CKD) with Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 * Severe chronic liver diseases with Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \> 3 Upper Limit of Normal (ULN) * Known gallbladder disease, including cholecystolithiasis * Creatinphosphokinase (CPK) \> 5 ULN at baseline * Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia * Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen, * Known allergy to peanut or arachis oil or soya lecithin or related products * Hypersensitivity to simvastatin or fenofibrate or to any of the excipients of the investigational drugs * Concomitant administration of potent cytochrome P450 isoenzyme 3A4 inhibitors (e.g. itraconazole, ketoconazole, fluconazole, posaconazole, Human Immunodeficiency Virus (HIV) protease inhibitors (e.g. nelfinavir), erythromycin, clarithromycin, telithromycin and nefazodone) * Pregnancy and lactation